Depressive symptoms and health-related quality of life in critical COVID-19 survivors: Preliminary results of 1-year follow-up

• Tipo: Outras Publicações
• Data: 2022

Autores

Martins, S (Autor) Outra; Fontes, L (Autor) Outra; Ferreira, AR (Autor) FMUP; Fernandes, J (Autor) Outra; Vieira, T (Autor) Outra; Reis, N (Autor) Outra; Braga, A (Autor) Outra; Coimbra, I (Autor) Outra; Paiva, J-A (Autor) FMUP; Lia Fernandes (Autor) FMUP

Outras Informações

ID Authenticus: P-00X-6BE

DOI: 10.1192/j.eurpsy.2022.793

Abstract (EN): <jats:sec id="S0924933822007933_sec04784" sec-type="intro"> <jats:title>Introduction</jats:title> <jats:p>A higher risk of mental health consequences in critical COVID-19 patients is expected due to several reasons, including prolonged mechanical ventilation with exposure to high sedation. In this context, post-discharge depression has been reported in previous COVID-19 studies, with a profound impact on patients¿ health-related quality of life (HRQoL).</jats:p> </jats:sec> <jats:sec id="S0924933822007933_sec04785"> <jats:title>Objectives</jats:title> <jats:p>To identify depressive symptoms in COVID-19 survivors 1-year after hospital discharge and to analyse its association with HRQoL.</jats:p> </jats:sec> <jats:sec id="S0924933822007933_sec04786" sec-type="methods"> <jats:title>Methods</jats:title> <jats:p>As part of the longitudinal MAPA project, this study enrolled critical COVID-19 patients admitted in the Intensive Care Medicine Department of a University Hospital (March-May 2020). Participants were assessed through telephone by an intensive care nurse and a psychologist, with the Patient Health Questionnaire (PHQ-9) (depressive symptoms), EuroQol five-dimension five-level questionnaire (EQ-5D-5L) and EQ-Visual Analogue Scale (EQ-VAS) (global health status patient record).</jats:p> </jats:sec> <jats:sec id="S0924933822007933_sec04787" sec-type="results"> <jats:title>Results</jats:title> <jats:p>A sample of 55 survivors (median age=66 years; 69% males) were included, with 20% showing depressive symptoms. Pain/discomfort (67%) and anxiety/depression (67%) were the most EQ-5D-5L domains reported. Survivors scoring for depression had more problems in all HRQoL areas (mobility:91%vs.48%, p=0.015; self-care:64%vs.27%, p=0.035; usual activities:91%vs.50%, p=0.017; pain/discomfort:100%vs.59%, p=0.010; anxiety/depression:100%vs.59%, p=0.010). Moreover, they had a lower EQ-VAS median, corresponding a worse self-perception of health status (50vs.80, p=0.010).</jats:p> </jats:sec> <jats:sec id="S0924933822007933_sec04788" sec-type="conclusions"> <jats:title>Conclusions</jats:title> <jats:p>Even after 1-year, a significant proportion of survivors presented depressive symptoms with repercussions in all HRQoL dimensions and association with worse self-perception of global quality of life. Taking this in mind, early screening and treatment of depression in COVID-19 survivors will be crucial, minimizing its impact on quality of life.</jats:p> </jats:sec> <jats:sec id="S0924933822007933_sec04789"> <jats:title>Disclosure</jats:title> <jats:p>No significant relationships.</jats:p> </jats:sec>

Idioma: Inglês

Tipo (Avaliação Docente): Científica